Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
But camizestrant’s use could depend on uptake of monitoring – for now.
Any hopes of differentiation could come down to side effects.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
